MIB-1 proliferation index in ductal carcinoma in situ of the breast: Relationship to the expression of the apoptosis-regulating proteins bcl-2 and p53

Breast Journal

Volumn 6, Issue 6, 2000, Pages 400-406

  Siziopikou, K P ^a   Schnitt, S J ^b  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b Department of Pathology ^*  (United States)

Author keywords

bcl 2; Breast; Ductal carcinoma in situ; MlB 1; p53; Tumor cell proliferation

Indexed keywords

MONOCLONAL ANTIBODY KI 67; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ANTIBODY LABELING; APOPTOSIS; ARTICLE; CARCINOMA IN SITU; CELL DEATH; CELL PROLIFERATION; CLINICAL ARTICLE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LABELING INDEX; PROTEIN EXPRESSION; TUMOR GROWTH;

EID: 0034523119     PISSN: 1075122X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4741.2000.99088.x     Document Type: Article

References (46)

1. BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death
2. Aptosis in cancer therapy: Crossing the threshold
3. Apoptosis. Its significance in cancer and cancer therapy
4. BAX suppresses tumorigenesis and stimulates apoptosis in vivo
5. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo
6. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype
7. Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2
8. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation
9. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67
10. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB1 and MIB3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections
11. Determination of proliferation index with MIB-1 in advanced ovarian cancer using quantitative image analysis
12. Usefulness of MIB-1 monoclonal antibody in assessing the proliferative index in human bladder carcinoma: Comparison with Ki-67 antibody
13. Cortical architectural abnormalities and MIB-1 immunoreactivity in gangliogliomas: A study of 60 patients with intracranial tumors
14. Proliferation markers in breast carcinoma: Mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1
15. MIB1 staining index and scoring of histologic features in meningioma. Indicators for the prediction of biologic potential and postoperative management
16. Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: Associations with other prognostic factors and survival
17. Cellular proliferation and prognosis in breast cancer: Statistical purity versus clinical utility
18. Correlation of Ki-67 antigen expression with mitotic figure index and tumor grade in breast carcinomas using the novel "paraffin"-reactive MIB1 antibody
19. Correlations of morphology, proliferation indices and oncogene activation in ductal breast carcinoma: Nuclear grade, S-phase, proliferating cell nuclear antigen, p53, epidermal growth factor receptor and c-erb-B-2
20. Relationship between p53 gene abnormalities and other tumour characteristics in breast cancer prognosis
21. Comparative prognostic value of Ki-67 and MIB-1 proliferation indices in breast cancer
22. Comparison of MIB-1 proliferation index with S-phase fraction in human breast carcinomas
23. Mammographically-detected ductal in situ carcinoma of the breast analyzed with a new classification. A study of 127 cases: Correlation with the estrogen and progesterone receptors, p53 and c-erb-B-2 proteins and proliferative activity
24. Cell kinetics of histologic variants of the in situ breast carcinoma
25. Pathology of in situ carcinoma
26. bcl-2 expression in the spectrum of preinvasive breast lesions
27. Ductal carcinoma in situ: A proposal for a new classification
28. Proliferation indices in solid tumors
29. Cell proliferation rate by MIB-1 immunohistochemistry predicts postradiation recurrence in prostatic adenocarcinomas
30. Bcl-2 oncoprotein positivity and high MIB-1 (Ki-67) proliferative rate are independent predictive markers for recurrence in prostate carcinoma
31. Utility of Ki-67 as a prognostic marker in pancreatic endocrine neoplasms; an editorial
32. Prognostic significance of MIB-1, p53, and bcl-2 immunoreactivity in meningiomas
33. Correlation of proliferation indices, apoptosis, and related oncogene expression (bcl-2 and c-erbB-2) and p53 in proliferative, hyperplastic, and malignant endometrium
34. Adjuvant therapy for node-negative breast cancer. The use of prognostic factors in selecting patients
35. The role of chemotherapy for node-negative breast cancer
36. Should all patients with node-negative breast cancer receive adjuvant therapy? Identifying additional subsets of low-risk patients who are highly curable by surgery alone
37. How to use prognostic factors in axillary node-negative breast cancer patients
38. Treatment of early-stage breast cancer
39. p53 protein expression, cell proliferation, and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast
40. Relationship of a new histological categorization of ductal carcinoma in situ of the breast with size and the immunohistochemical expression of p53, c-erbB-2, bcl-2 and Ki-67
41. bcl-2 in normal human breast and carcinoma; association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer
42. The Bcl-2 protein: A prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients
43. Bcl-2 protein expression and long-term survival in breast cancer
44. Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity
45. bcl-2 expression in breast carcinoma
46. Down-regulation of bcl-2 by p53 in breast cancer cells